Events

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma

Alert-Based ePRO Monitoring Reduces Fatigue in Metastatic Breast Cancer

ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer

Atezolizumab Elicits Durable Responses in R/R Extranodal NK/T-Cell Lymphoma

FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma